Rigel Pharmaceuticals Files 8-K on Financials
Ticker: RIGL · Form: 8-K · Filed: May 6, 2025 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | 8-K |
| Filed Date | May 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Rigel Pharma filed an 8-K on May 6th about their financials. Details inside.
AI Summary
Rigel Pharmaceuticals, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, but does not disclose specific financial figures or operational updates within the provided text.
Why It Matters
This 8-K filing indicates Rigel Pharmaceuticals is providing updates on its financial condition and operations to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting financial information and does not contain any immediately alarming or negative news.
Key Players & Entities
- RIGEL PHARMACEUTICALS, INC. (company) — Registrant
- May 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State or other jurisdiction of incorporation
- 611 Gateway Boulevard Suite 900 (address) — Address of principal executive offices
- South San Francisco (city) — City of principal executive offices
- CA (state) — State of principal executive offices
- 94080 (zip_code) — Zip code of principal executive offices
- ( 650 ) 624-1100 (phone_number) — Registrant's telephone number
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text for the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but it does not contain the specific details of these results or updates.
When was the earliest event reported in this Form 8-K?
The earliest event reported in this Form 8-K was on May 6, 2025.
What is the principal executive office address for Rigel Pharmaceuticals, Inc.?
The principal executive office address for Rigel Pharmaceuticals, Inc. is 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What is the Standard Industrial Classification code for Rigel Pharmaceuticals, Inc.?
The Standard Industrial Classification code for Rigel Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding RIGEL PHARMACEUTICALS INC (RIGL).